Outcome of the Board Meeting
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shilpa Medicare reported strong FY2026 results with standalone revenue of Rs 59,703 Lakhs (up 25% YoY) and net profit of Rs 13,297 Lakhs (up 96% YoY) with EPS of Rs 6.80. Consolidated revenue stood at Rs 153,887 Lakhs with net profit of Rs 24,333 Lakhs. The Board recommended a final dividend of Rs 0.60 per share (60%) for FY2025-26, subject to shareholder approval. Key corporate actions include shifting the registered office from Karnataka to Maharashtra (via postal ballot), appointment of new Cost Auditors (V.J. Talati & Co) and Internal Auditors (Aneja Associates), and investment of Rs 4.44 Crore for 28% stake in Neo Green Power Project Private Limited to meet captive power requirements. The auditor gave an unmodified opinion on the financials.
The strong financial performance with near-doubling of standalone net profit and declaration of dividend should be positive for shareholders. The strategic investment in renewable energy for captive consumption indicates forward-looking cost management. The proposed relocation to Maharashtra may offer operational benefits but requires shareholder approval.